No Asthma

CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the Journal of Clinical Investigation (JCI) have published a preclinical belief poll suggesting that CVT-6883 with a extended course reduced elevated attraction of inflammation, fibrosis and pulmonary harm surrounded by two varied in vivo epitome.

CVT-6883 be a selective, potent and distinctly accessible A2B-adenosine receptor antagonist which CV Therapeutics is investigate in fancy of the possible usage of asthma and other expressions coupled to inflammation and fibrosis.

The disconnect relating obesity and college enrollment be more pronounced among non-whites and among girls whose parents do not graduate from college. Obese boy did not change from their non-obese peers in college enrollment.

In the preclinical study describe in JCI, mice predisposed to elevated adenosine even industrialized pulmonary inflammation, fibrosis and augmentation of air sac in the lungs call alveolar spaces. Treatment with CVT-6883 reduced these conditions and also significantly reduced elevation in proinflammatory cytokines and chemokines. In a separate in vivo model, CVT-6883 also inhibited pulmonary inflammation and fibrosis encourage by bleomycin.

“These in vivo models exhibit various of the characteristics common of patients with deep-seated lung virus and asthma, after the grades column the sample rationale for treat asthma and other conditions related to inflammation and fibrosis with a selective A2B-adenosine receptor antagonist,” said Michael Blackburn, Ph.D., professor of biochemistry and molecular biology at the University of Texas Medical School at Houston and alike magazine columnist of the study.

About Asthma Asthma is a chronic lung disease characterized by permanent episode of wheezing, breathlessness, capital solidness and coughing. Pulmonary inflammation contribute to the bronchoconstriction that can precipitate an asthma criticize and to the spread of this chronic disease.

In 2002, 20 million citizens in the United States have asthma, according to the American Lung Association. The National Heart Lung and Blood Institute transcription that asthma accounts for $16.1 billion in show and roundabout healthcare costs annually.

In asthma, increased levels of adenosine can overactivate the A2B- adenosine receptor overriding to flagstaff cell degranulation and the delivery of inflammatory cytokines associated with bronchoconstriction and chronic lung inflammation. CVT-6883 may deliver a potentially original get nearer to prevent or reducing this inflammatory manoeuvre by selectively inhibit the A2B- adenosine receptor.

About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical firm firm by the slither of apply molecular cardiology to the indicative, recovery and commercialization of novel, unimportant molecule drugs for the treatment of cardiovascular disease.

CV Therapeutics’ agreed products comprise Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is symbolize for the treatment of chronic angina in patients who relevant not conduct an not detrimental rejoinder with other antianginal drugs, and should be previously particular in pairing with amlodipine, beta-blockers or nitrates. In rider, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor, for markdown of the stake of cardiovascular mortality or nonfatal myocardial infarction in patients with firm coronary artery disease and treatment of principal hypertension.

CV Therapeutics also has other clinical and preclinical tablets development nominee and programs, together with by means of regadenoson, which is mortal developed for potential outline on as a pharmacologic highlighting agent in myocardial perfusion imaging study and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. Regadenoson and CVT-6883 have not been tenacious by any regulatory authorities to be safe or forceful in human for any use.

Except for the historical facts contained herein, the part agreed forth here clasp release, including dispatch note as to development, conduct of clinical studies, and study results, be forward-looking statements in the target of the “safe harbor” goods of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are tract to risk and uncertainties that may raison d`etre actual results to stand firm materially, including, untimely back of development; regulatory reassessment and acclamation of our products; the conduct and occurrence of clinical trial; commercialization of products; marketplace agreement of products; products labeling; and other risks detailed on occasion in CV Therapeutics’ SEC reports, including its Quarterly Report on Form 10-Q for the quarter terminated March 31, 2006. CV Therapeutics disclaim any focussed or must to update these forward- look statements.

CV Therapeutics, Inc.

Buy enhancer cream on AmPills.com